Cinta Pallarés

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer

Ricardo Hitt, Antonio López–Pousa, Javier Martínez‐Trufero et al. · Journal of Clinical Oncology · 2005 · 454 citations

Medicine, Oncology, Radiation Oncology +15

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

Mark A. Socinski, Silvia Novello, Julie R. Brahmer et al. · Journal of Clinical Oncology · 2008 · 321 citations · Full text

Medicine, Oncology, Pharmacology +17

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

R. Rosell, R. Gervais, A. Vergnenègre et al. · Journal of Clinical Oncology · 2011 · 148 citations

Medicine, Oncology, Pharmacology +16

Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients

Esther Roé, Maria Pilar García Muret, Eugenio Marcuello et al. · Journal of the American Academy of Dermatology · 2006 · 145 citations

Pharmacy, Oncology, Pharmacotherapy +15